Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Mannkind’s Inhaled Clofazimine Will Advance To An Adaptive Phase 2 3 Study For Potential Treatment Of Rare Lung Disease is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease - WSPA 7News
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled ... Read More
Latest Press Release on Respiratory Disease News - Medindia
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial ... to initiate the Phase 3 study (ICoN-1) of Clofazimine Inhalation Suspension for the treatment of NTM lung disease. Read More
First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM ...
ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to ... S&P 500. NASDAQ 100. EURO STOXX 50. FTSE-100. SMI. ATX. NIKKEI. HANG SENG ... Read More
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous ...
Clearance to proceed also received from health authorities in South Korea and Australia, with Taiwan expected in 4Q 2024First U.S. patient randomized DANBURY, Conn., Sept. 18, 2024 (GLOBE NEWSWIRE ... Read More
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease - KOLR - OzarksFirst.com
Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overcomes systemic toxicity and lessens side ... Read More
First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM ...
ICoN-1 study presentation planned November 1 at NTM Symposium Australia Study is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus